New developments in focal therapy for prostate cancer
Prostate cancer remains the most commonly diagnosed solid malignancy in Australian men, with more than 24,000 new cases recorded each year and a survival rate that has climbed steadily thanks to earlier detection through PSA testing. In major centres such as Sydney, Melbourne, Brisbane and Perth, urologists are increasingly turning away from whole-gland radical treatment for carefully selected men with low- to intermediate-risk disease. Focal therapy sits at the centre of this shift, offering targeted ablation of the index lesion while preserving the rest of the prostate gland. The aim is straightforward but ambitious: meaningful oncological control without the urinary, sexual and bowel consequences that often follow prostatectomy or whole-gland radiotherapy.
The Australian urological community has watched the global evidence base mature rapidly, with several pivotal trials concluding in 2024 and 2025 and new devices entering local practice. Medicare funding for some ablative procedures remains patchy, but private insurers in New South Wales and Victoria are starting to recognise focal HIFU and focal cryotherapy in their schedules. Patients now arrive at consults armed with information from online forums, support groups and sometimes overseas centres, and they expect clinicians to be conversant with the latest data. This article reviews where focal therapy for prostate cancer currently stands, which modalities are gaining traction, and what the next five years are likely to bring.
What focal therapy actually delivers
Focal therapy is best understood as a middle path between active surveillance and radical intervention. Rather than treating the entire gland, the urologist uses imaging guidance to destroy only the area of clinically significant cancer, typically defined as Gleason 3+4 or higher on targeted biopsy. The index lesion hypothesis underpins the approach: most lethal prostate cancers originate from a single dominant focus, and treating that focus can deliver disease control comparable to whole-gland therapy while leaving the surrounding tissue untouched.
Clinical outcomes from prospective registries in the United Kingdom and Europe now show five-year salvage-treatment-free survival rates of around 85 to 90 percent in well-selected men. Functional recovery is where the technique truly distinguishes itself, with pad-free continence rates exceeding 95 percent and preserved erectile function in roughly 70 to 80 percent of potent men at twelve months. These numbers have prompted a quiet change in how Australian specialists counsel newly diagnosed patients, particularly those in their fifties and early sixties for whom decades of life remain.
Imaging and targeting have caught up with the concept
Focal therapy was always conceptually appealing, but for years it outran the imaging technology needed to make it reliable. That gap has closed. Multiparametric MRI, now standard in most Australian radiology departments, allows clinicians to identify suspicious lesions as small as five millimetres, and PSMA PET/CT is increasingly used when MRI findings are equivocal or when biochemical recurrence is suspected.
Artificial intelligence is sharpening the picture further. Several platforms approved by the TGA in 2023 and 2024 can co-register MRI with live transrectal ultrasound, producing real-time three-dimensional maps that help the operator place ablation probes with millimetric precision. The result is a tighter treatment margin, fewer retreatments, and greater confidence when offering focal therapy to men with multifocal disease. For clinicians accustomed to the limitations of cognitive fusion, this is a meaningful leap forward.
| Modality | Mechanism | Typical candidates | Key advantage | Main limitation |
|---|---|---|---|---|
| Focal HIFU | Ultrasound-induced thermal ablation | Uni- or bilateral low-intermediate risk lesions | Non-invasive, repeatable | Longer procedure time |
| Focal cryotherapy | Freeze-thaw cycles | Posterior and apical lesions | Real-time ice-ball visualisation | Post-procedural retention risk |
| Irreversible electroporation | Non-thermal cell membrane disruption | Lesions near neurovascular bundles | Spares collagenous structures | Limited long-term data |
| Focal brachytherapy | Low-dose-rate seed implantation | Lower-volume disease | Single outpatient session | Requires specialist centre |
| Laser interstitial therapy | Photothermal ablation | Small, well-defined lesions | MRI-compatible applicators | Smaller ablation zones |
High-intensity focused ultrasound comes of age
Focal HIFU has the longest track record of any focal modality and continues to evolve. The Sonablate and Focal One platforms both have TGA approval and are available in Australian private hospitals, including several sites in Sydney and Melbourne. The recent introduction of automated segmentation and motion compensation has shortened learning curves and improved consistency between operators, addressing one of the historic criticisms of ultrasound-based ablation.
Outcome data from the INDEX trial and from a large prospective European registry suggest that focal HIFU achieves high rates of clinically significant cancer absence on follow-up biopsy at twenty-four months, with serious adverse events remaining rare. For Australian men with a single visible lesion and no prior treatment, focal HIFU is now a reasonable first-line option to discuss alongside active surveillance.
Cryotherapy, electroporation and the non-thermal alternative
Cryoablation was among the first focal approaches widely adopted, and second-generation needle-based systems allow the urologist to sculpt ice-ball coverage with much greater precision than the original whole-gland templates. The technique is particularly useful for posterior lesions adjacent to the rectum, where real-time transrectal ultrasound monitoring helps protect surrounding structures. Australian experience at high-volume centres in Victoria and Western Australia suggests that focal cryotherapy delivers functional outcomes broadly comparable to HIFU, with slightly higher rates of transient urinary retention.
Irreversible electroporation, sometimes called NanoKnife, takes a completely different approach. Short, high-voltage electrical pulses create permanent nanopores in cell membranes, causing apoptosis without the heat or cold of traditional ablation. Because the technology spares collagen and elastin, it is favoured for lesions close to the neurovascular bundles where preservation of erectile function is paramount. Mid-term oncological data are encouraging, though longer follow-up is needed before it can be considered a standard option.
Selecting the right patient in Australian practice
Patient selection is everything in focal therapy, and Australian guidelines now mirror international consensus. Ideal candidates are men with ISUP grade group 2 or 3 disease, a visible lesion on mpMRI concordant with targeted biopsy, and a prostate volume under 40 millilitres. Men with high-volume Gleason 4+3, multiparametric MRI suggesting extracapsular extension, or a strong family history warrant caution, and many specialists in Sydney's Royal Prince Alfred Hospital and Melbourne's Peter MacCallum Cancer Centre will still steer such patients toward radical treatment.
Shared decision-making is the heart of the consult. The Australasian Prostate Cancer Outcomes Registry has shown wide variation in how men perceive the trade-off between cancer control and quality of life, and a thoughtful conversation about salvage options if focal therapy fails is essential. Practical considerations matter too: men in rural Queensland or Western Australia may struggle to access the multiparametric MRI follow-up that focal therapy requires, and this should be discussed openly before proceeding. For men weighing post-treatment urinary symptoms, a review of novel bladder pharmacotherapies can be a useful adjunct during counselling, and parents considering hypospadias repair outcomes in their sons will recognise the same principles of tissue-sparing reconstruction echoed in modern prostate practice.
Future directions and what to watch
The next wave of focal therapy research is moving toward combination strategies. Sequential HIFU followed by focal brachytherapy, or HIFU combined with systemic androgen-receptor-pathway inhibitors in higher-risk disease, are already being trialled in early-phase studies. Biomarker-driven patient selection, using genomic classifiers such as Decipher or Prolaris, is likely to refine the candidate pool further, helping clinicians identify men whose biology is genuinely suited to a tissue-preserving approach.
For Australian urologists, the priorities are clearer follow-up protocols, equitable access in the public system, and continued engagement with international registries so that local outcomes can be benchmarked honestly. Patients should be encouraged to ask about their clinician's personal case volume, the imaging platform in use, and the institution's participation in ongoing trials. Recovery days can be long, and some patients fill them with quiet pastimes ranging from audiobooks and gentle walking to the occasional baccarat live dealer game on a tablet, though clinicians continue to emphasise that mental rest and graded physical activity remain the cornerstones of convalescence; for staged return to heavy lifting, men can also consult resources that outline lifting restrictions after surgery in plain language.
The era of one-size-fits-all prostate cancer care is drawing to a close, and focal therapy is the most tangible expression of that change across Australian urology. Clinicians are encouraged to review their current patient pathways, raise focal options in their next multidisciplinary meeting, and consider referring suitable candidates to a centre with an active focal therapy programme. Patients keen to read further can explore the journal's growing collection of focal therapy reviews, technique videos, and long-term outcome studies, and are invited to submit their own case reflections to continue building the local evidence base.